Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

2.3K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.3K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.1K
Classification of Leukocytes01:30

Classification of Leukocytes

6.9K
Leukocytes are classified into two groups based on the presence or absence of cytoplasmic granules. Granular leukocytes, which contain granules, belong to the myeloid lineage and are divided into three subtypes: neutrophils, eosinophils, and basophils. These cells are roughly spherical and characterized by the granules in their cytoplasm.
Neutrophils are the most abundant type of granular leukocytes, comprising 50-70% of all leukocytes. They feature small, evenly distributed granules and a...
6.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A case of true acute eosinophilic leukemia arising from myelodysplastic syndrome.

Journal of hematopathology·2026
Same author

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases.

Frontiers in immunology·2026
Same author

Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.

Journal of hematology & oncology·2026
Same author

Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.

Nature medicine·2026
Same author

Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years.

The Journal of allergy and clinical immunology·2026

Related Experiment Video

Updated: Mar 9, 2026

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

12.5K

Myeloid neoplasms with eosinophilia.

Andreas Reiter1, Jason Gotlib2

  • 1Department of Hematology and Oncology, University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany; and.

Blood
|December 29, 2016
PubMed
Summary

Molecular diagnostics identify fusion tyrosine kinase (TK) genes in myeloid neoplasms with eosinophilia. Targeted therapies improve outcomes for some, while others require stem cell transplantation.

More Related Videos

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

2.0K
A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

21.4K

Related Experiment Videos

Last Updated: Mar 9, 2026

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

12.5K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

2.0K
A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

21.4K

Area of Science:

  • Hematology
  • Molecular Oncology
  • Genetics

Background:

  • Myeloid neoplasms with eosinophilia are a heterogeneous group of disorders.
  • Fusion tyrosine kinase (TK) genes, such as PDGFRA, PDGFRB, FGFR1, and JAK2, are key drivers in a subset of these diseases.
  • These genetic alterations can lead to myeloproliferative neoplasms (MPN), myelodysplastic/MPN, or mixed-phenotype leukemias.

Purpose of the Study:

  • To review the molecular landscape of myeloid neoplasms with eosinophilia.
  • To discuss the clinical implications of specific genetic rearrangements, particularly fusion TK genes.
  • To highlight the impact of targeted therapies and allogeneic stem cell transplantation on patient outcomes.

Main Methods:

  • Review of current literature and World Health Organization (WHO) classifications.
  • Analysis of diagnostic and prognostic implications of molecular alterations.
  • Correlation of genetic findings with clinical presentation and treatment response.

Main Results:

  • Rearrangements of PDGFRA and PDGFRB have significantly improved prognoses with imatinib therapy.
  • FGFR1 and JAK2 fusion TK gene rearrangements are associated with aggressive disease and variable response to TK inhibitors, often necessitating allogeneic stem cell transplantation.
  • FLT3 and ABL1 rearrangements also portend poor prognosis, warranting further investigation for inclusion in WHO-defined categories.
  • Molecular profiling is reclassifying cases previously diagnosed as hypereosinophilic syndrome.

Conclusions:

  • Molecular diagnostics are crucial for precise classification and prognostication of myeloid neoplasms with eosinophilia.
  • Targeted therapies have revolutionized treatment for some TK fusion-driven neoplasms.
  • Allogeneic stem cell transplantation remains a critical option for high-risk disease.
  • Future challenges include integrating molecular profiling data for personalized treatment strategies.